HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
CHENGDU, China, July 14, 2026 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. (“BioAge”, NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic
